This page shows the latest RG3039 news and features for those working in and with pharma, biotech and healthcare.
Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m. ... $5m. The main candidate involved in the programme is RG3039, which will undergo phase I trials carried out by Repligen in the first quarter of 2013.
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
This programme includes RG3039, a small molecule drug candidate in clinical development, as well as backup compounds and enabling technologies. ... Licence. RG3039 orphan for spinal muscular atrophy. 70. Amplimmune / Daiichi Sankyo.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...